Camurus AB
STO:CAMX

Watchlist Manager
Camurus AB Logo
Camurus AB
STO:CAMX
Watchlist
Price: 680 SEK -0.07% Market Closed
Updated: Aug 14, 2024
Have any thoughts about
Camurus AB?
Write Note

Profitability Summary

Camurus AB's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Camurus AB

Revenue
1.6B SEK
Cost of Revenue
-127.2m SEK
Gross Profit
1.5B SEK
Operating Expenses
-1.2B SEK
Operating Income
236.8m SEK
Other Expenses
-13.5m SEK
Net Income
223.3m SEK

Margins Comparison
Camurus AB Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
SE
Camurus AB
STO:CAMX
39.3B SEK
92%
15%
14%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
883B USD
81%
35%
19%
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK
85%
45%
37%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
381.7B USD
69%
29%
44%
US
Merck & Co Inc
NYSE:MRK
284.9B USD
76%
29%
22%
UK
AstraZeneca PLC
NASDAQ:AZN
256.9B USD
82%
21%
13%
CH
Roche Holding AG
SIX:ROG
222.4B CHF
73%
32%
20%
CH
Novartis AG
SIX:NOVN
191.1B CHF
75%
29%
33%
US
Pfizer Inc
NYSE:PFE
163.7B USD
71%
19%
-5%
Country SE
Market Cap 39.3B SEK
Gross Margin
92%
Operating Margin
15%
Net Margin
14%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 883B USD
Gross Margin
81%
Operating Margin
35%
Net Margin
19%
Country DK
Market Cap 4T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
37%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country US
Market Cap 381.7B USD
Gross Margin
69%
Operating Margin
29%
Net Margin
44%
Country US
Market Cap 284.9B USD
Gross Margin
76%
Operating Margin
29%
Net Margin
22%
Country UK
Market Cap 256.9B USD
Gross Margin
82%
Operating Margin
21%
Net Margin
13%
Country CH
Market Cap 222.4B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country CH
Market Cap 191.1B CHF
Gross Margin
75%
Operating Margin
29%
Net Margin
33%
Country US
Market Cap 163.7B USD
Gross Margin
71%
Operating Margin
19%
Net Margin
-5%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Camurus AB Competitors

Country Company Market Cap ROE ROA ROCE ROIC
SE
Camurus AB
STO:CAMX
39.3B SEK
10%
9%
11%
20%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
883B USD
60%
12%
33%
19%
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK
100%
33%
87%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
381.7B USD
53%
20%
19%
14%
US
Merck & Co Inc
NYSE:MRK
284.9B USD
33%
13%
21%
17%
UK
AstraZeneca PLC
NASDAQ:AZN
256.9B USD
17%
6%
14%
12%
CH
Roche Holding AG
SIX:ROG
222.4B CHF
40%
13%
29%
22%
CH
Novartis AG
SIX:NOVN
191.1B CHF
35%
16%
20%
15%
US
Pfizer Inc
NYSE:PFE
163.7B USD
-3%
-1%
7%
4%
Country SE
Market Cap 39.3B SEK
ROE
10%
ROA
9%
ROCE
11%
ROIC
20%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 883B USD
ROE
60%
ROA
12%
ROCE
33%
ROIC
19%
Country DK
Market Cap 4T DKK
ROE
100%
ROA
33%
ROCE
87%
ROIC
36%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country US
Market Cap 381.7B USD
ROE
53%
ROA
20%
ROCE
19%
ROIC
14%
Country US
Market Cap 284.9B USD
ROE
33%
ROA
13%
ROCE
21%
ROIC
17%
Country UK
Market Cap 256.9B USD
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country CH
Market Cap 222.4B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country CH
Market Cap 191.1B CHF
ROE
35%
ROA
16%
ROCE
20%
ROIC
15%
Country US
Market Cap 163.7B USD
ROE
-3%
ROA
-1%
ROCE
7%
ROIC
4%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top